# Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)

> **NCT00007189** · PHASE3 · COMPLETED · sponsor: **Seattle Institute for Biomedical and Clinical Research** · enrollment: 2625 (—)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Naproxen Sodium (Aleve)
- **DRUG:** Celecoxib (Celebrex)

## Key facts

- **NCT ID:** NCT00007189
- **Lead sponsor:** Seattle Institute for Biomedical and Clinical Research
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-01
- **Primary completion:** 2007-05
- **Final completion:** —
- **Target enrollment:** 2625 (—)
- **Last updated:** 2016-10-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00007189

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00007189, "Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00007189. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*